A5002087563- HER2/EGFR in Cancer Research
- S100 Proteins and Annexins
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Molecular Biology Techniques and Applications
- Prostate Cancer Treatment and Research
- Estrogen and related hormone effects
- Chronic Lymphocytic Leukemia Research
- Protease and Inhibitor Mechanisms
- Chronic Myeloid Leukemia Treatments
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Surgical site infection prevention
- Cellular Mechanics and Interactions
- Health disparities and outcomes
- Colorectal Cancer Surgical Treatments
- Ubiquitin and proteasome pathways
- Barrier Structure and Function Studies
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Health and Medical Studies
- Social and Demographic Issues in Germany
- Clusterin in disease pathology
- Antimicrobial Peptides and Activities
- Cancer Treatment and Pharmacology
Dublin City University
2022-2025
University of Limerick
2018-2025
HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition therapeutic resistance due compensatory receptor crosstalk. New drug combinations targeting HER2 and ER could improve outcomes for patients with HER2+/ER+ cancer. In this study, pre-clinical rationale is explored combining amcenestrant (Amc), selective oestrogen degrader (SERD), HER2-targeted therapies including...
Drug efflux transporter associated multi-drug resistance (MDR) is a potential limitation in the use of taxane chemotherapies for treatment metastatic melanoma. ABT-751 an orally bioavailable microtubule-binding agent capable overcoming MDR and proposed as alternative to taxane-based therapies.
When breast cancer progresses to a metastatic stage, survival rates decline rapidly and it is considered incurable. Thus, deciphering the critical mechanisms of metastasis vital importance develop new treatment options. We hypothesize that studying proteins are newly synthesized during processes migration invasion will greatly enhance our understanding progression. conducted mass spectrometry screen following bioorthogonal noncanonical amino acid tagging elucidate changes in nascent proteome...
Introduction The extracellular matrix (ECM) has been heavily implicated in the development and progression of cancer. We have previously shown that Annexin A2 is integral migration invasion breast cancer cells clinical ER-negative cancer, processes which are highly influenced by surrounding tumor microenvironment ECM. Methods investigated how modulations ECM may affect role MDA-MB-231 using western blotting, immunofluorescent confocal microscopy immuno-precipitation mass spectrometry...
HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or emergence acquired is a persistent clinical problem. Here we report that neratinib, an irreversible pan-HER inhibitor, in combination with multi-kinase inhibitor dasatinib, currently used to treat certain leukemias, has strong anti-proliferative effects against models cancer are innately resistant trastuzumab neratinib.
Abstract Background: Targeting the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors with small molecule TKIs lapatinib, neratinib and tucatinib, monoclonal antibodies like trastuzumab more recently ADCs T-DM1 T-DXd has resulted in improved survival rates for patients HER2+ BC. are primarily utilised trastuzumab-refractory disease. Neratinib, pan-HER TKI afatinib, bind irreversibly to all members HER family, while lapatinib binds reversibly HER2 EGFR, tucatinib...
Abstract Background: Up to 70% of HER2 over-expressing (HER2+) breast cancers also express estrogen receptor (ER). Dual targeting and ER has shown pre-clinical clinical benefit in HER2+/ER+ cancer. Rationale for these combinations is based on circumvention resistance mediated by crosstalk between signalling pathways. Fulvestrant the only selective degrader (SERD) approved FDA treatment ER+ Development alternative orally available SERDs with improved bioavailability, such as amcenestrant,...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Background: In Ireland, almost three thousand women are diagnosed with invasive breast cancer every year. Of those diagnosed, approximately 1/5 affected by triple negative (TNBC), a sub-type characterised an aggressive phenotype and poor prognosis. The lack of expression common pharmacological targets, i.e., the estrogen receptor, progesterone receptor human epidermal growth 2, means that current treatment is limited to traditional chemotherapeutics. As result, there urgent need identify...
Abstract Triple negative breast cancer (TNBC) is a distinct subtype of defined by tumours deficient in the expression three main immuno-histochemical markers: estrogen receptor (ER), progesterone (PR) and human epidermal growth 2 (HER2). Although accounting for only 15-20% total cancer, TNBC characterized an aggressive phenotype poor prognosis. As result, it cause disproportionate amount deaths, with higher incidence amongst younger women ethnic minorities. In addition, lack ER, PR HER2...
Background: Increased glucose metabolism under aerobic conditions is a well-known hallmark of cancer, first described by Otto Warburg in the 1920s. This characteristic upregulation necessary to provide energy for replication and forms basis much study cancer research.
Abstract Breast cancer is the most frequently invasive type among women worldwide, accounting for over 2 million new cases annually and 25% of all cancers diagnosed in women. Considering significant advances diagnostics treatment breast it remains a leading cause mortality worldwide. The extracellular matrix (ECM) meshwork fibrous proteins proteoglycans that essential providing physical framework facilitating biochemical cues to maintain tissue homeostasis. However, ECM also has...
In Ireland, almost three thousand women are diagnosed with invasive breast cancer every year. This makes it the most common form of malignant tumour found in Irish females and accounts for 17% all female deaths. Although treatment when early is highly effective, those who develop late stage metastatic cancer, survival rates decline rapidly. As a result, large effort being made to understand mechanisms involved progression identifying changes that take place during in-situ transition.Using...
Breast cancer is the most frequently invasive type among women worldwide, accounting for over 2 million new cases annually and 25% of all cancers diagnosed in women. Considering significant advances diagnostics treatment breast it remains a leading cause mortality worldwide. The extracellular matrix (ECM) meshwork fibrous proteins proteoglycans that essential providing physical framework facilitating biochemical cues to maintain tissue homeostasis. However, ECM also has well-established role...
Abstract In Ireland, almost three thousand women are diagnosed with invasive breast cancer every year. This makes it the most common form of malignant tumour found in Irish females and accounts for 17% all female deaths. Although treatment when early is highly effective, those who develop late stage metastatic cancer, survival rates decline rapidly. As a result, large effort being made to understand mechanisms involved progression identifying changes that take place during in-situ...
Abstract Background: HER2-positive (+) breast cancer (BC) represents a significant clinical burden due to an aggressive phenotype and propensity for brain metastasis. Up 70 % of HER2+ BCs are also oestrogen receptor (ER)-positive, with crosstalk often attributed anti-HER2 therapeutic resistance. Neratinib is pan-HER tyrosine kinase inhibitor, currently approved the treatment BC. Dual-blockade endocrine therapies (ETs) has shown positive outcomes in trials, without added toll traditional...
Abstract Breast cancer is the most prevalent form of worldwide, with surgery remaining a standard treatment. Although treatable disease, survival rate improving due to enhancements in screening and treatment, recurrence remains dominant contributor breast related deaths. It has been suggested that systemic factors during postoperative period, such as surgical site infection (SSI), may increase risk recurrence, although exact role these infections play yet be elucidated. To investigate...